These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 24637359)

  • 21. Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy.
    Mount JD; Herzog RW; Tillson DM; Goodman SA; Robinson N; McCleland ML; Bellinger D; Nichols TC; Arruda VR; Lothrop CD; High KA
    Blood; 2002 Apr; 99(8):2670-6. PubMed ID: 11929752
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy.
    Niemeyer GP; Herzog RW; Mount J; Arruda VR; Tillson DM; Hathcock J; van Ginkel FW; High KA; Lothrop CD
    Blood; 2009 Jan; 113(4):797-806. PubMed ID: 18957684
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant.
    George LA; Sullivan SK; Giermasz A; Rasko JEJ; Samelson-Jones BJ; Ducore J; Cuker A; Sullivan LM; Majumdar S; Teitel J; McGuinn CE; Ragni MV; Luk AY; Hui D; Wright JF; Chen Y; Liu Y; Wachtel K; Winters A; Tiefenbacher S; Arruda VR; van der Loo JCM; Zelenaia O; Takefman D; Carr ME; Couto LB; Anguela XM; High KA
    N Engl J Med; 2017 Dec; 377(23):2215-2227. PubMed ID: 29211678
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B.
    Nathwani AC; Tuddenham EG; Rangarajan S; Rosales C; McIntosh J; Linch DC; Chowdary P; Riddell A; Pie AJ; Harrington C; O'Beirne J; Smith K; Pasi J; Glader B; Rustagi P; Ng CY; Kay MA; Zhou J; Spence Y; Morton CL; Allay J; Coleman J; Sleep S; Cunningham JM; Srivastava D; Basner-Tschakarjan E; Mingozzi F; High KA; Gray JT; Reiss UM; Nienhuis AW; Davidoff AM
    N Engl J Med; 2011 Dec; 365(25):2357-65. PubMed ID: 22149959
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Liver-specific transcriptional modules identified by genome-wide in silico analysis enable efficient gene therapy in mice and non-human primates.
    Chuah MK; Petrus I; De Bleser P; Le Guiner C; Gernoux G; Adjali O; Nair N; Willems J; Evens H; Rincon MY; Matrai J; Di Matteo M; Samara-Kuko E; Yan B; Acosta-Sanchez A; Meliani A; Cherel G; Blouin V; Christophe O; Moullier P; Mingozzi F; VandenDriessche T
    Mol Ther; 2014 Sep; 22(9):1605-13. PubMed ID: 24954473
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Improved hepatic gene transfer by using an adeno-associated virus serotype 5 vector.
    Mingozzi F; Schüttrumpf J; Arruda VR; Liu Y; Liu YL; High KA; Xiao W; Herzog RW
    J Virol; 2002 Oct; 76(20):10497-502. PubMed ID: 12239326
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BAX 335 hemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expression.
    Konkle BA; Walsh CE; Escobar MA; Josephson NC; Young G; von Drygalski A; McPhee SWJ; Samulski RJ; Bilic I; de la Rosa M; Reipert BM; Rottensteiner H; Scheiflinger F; Chapin JC; Ewenstein B; Monahan PE
    Blood; 2021 Feb; 137(6):763-774. PubMed ID: 33067633
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of the vector genome and underlying factor IX mutation in immune responses to AAV gene therapy for hemophilia B.
    Rogers GL; Martino AT; Zolotukhin I; Ertl HC; Herzog RW
    J Transl Med; 2014 Jan; 12():25. PubMed ID: 24460861
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Incorporation of the factor IX Padua mutation into FIX-Triple improves clotting activity in vitro and in vivo.
    Kao CY; Yang SJ; Tao MH; Jeng YM; Yu IS; Lin SW
    Thromb Haemost; 2013 Aug; 110(2):244-56. PubMed ID: 23676890
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CRISPR/Cas9-mediated in vivo gene targeting corrects hemostasis in newborn and adult factor IX-knockout mice.
    Wang L; Yang Y; Breton CA; White J; Zhang J; Che Y; Saveliev A; McMenamin D; He Z; Latshaw C; Li M; Wilson JM
    Blood; 2019 Jun; 133(26):2745-2752. PubMed ID: 30975639
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Liver gene therapy by lentiviral vectors reverses anti-factor IX pre-existing immunity in haemophilic mice.
    Annoni A; Cantore A; Della Valle P; Goudy K; Akbarpour M; Russo F; Bartolaccini S; D'Angelo A; Roncarolo MG; Naldini L
    EMBO Mol Med; 2013 Nov; 5(11):1684-97. PubMed ID: 24106222
    [TBL] [Abstract][Full Text] [Related]  

  • 32. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B.
    Manno CS; Chew AJ; Hutchison S; Larson PJ; Herzog RW; Arruda VR; Tai SJ; Ragni MV; Thompson A; Ozelo M; Couto LB; Leonard DG; Johnson FA; McClelland A; Scallan C; Skarsgard E; Flake AW; Kay MA; High KA; Glader B
    Blood; 2003 Apr; 101(8):2963-72. PubMed ID: 12515715
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector.
    Kay MA; Manno CS; Ragni MV; Larson PJ; Couto LB; McClelland A; Glader B; Chew AJ; Tai SJ; Herzog RW; Arruda V; Johnson F; Scallan C; Skarsgard E; Flake AW; High KA
    Nat Genet; 2000 Mar; 24(3):257-61. PubMed ID: 10700178
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Peripheral transvenular delivery of adeno-associated viral vectors to skeletal muscle as a novel therapy for hemophilia B.
    Arruda VR; Stedman HH; Haurigot V; Buchlis G; Baila S; Favaro P; Chen Y; Franck HG; Zhou S; Wright JF; Couto LB; Jiang H; Pierce GF; Bellinger DA; Mingozzi F; Nichols TC; High KA
    Blood; 2010 Jun; 115(23):4678-88. PubMed ID: 20335222
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of adeno-associated viral vectors based on serotype 8 and 9 vs. lentiviral vectors for hemophilia B gene therapy.
    Vandendriessche T; Thorrez L; Acosta-Sanchez A; Petrus I; Wang L; Ma L; DE Waele L; Iwasaki Y; Gillijns V; Wilson JM; Collen D; Chuah MK
    J Thromb Haemost; 2007 Jan; 5(1):16-24. PubMed ID: 17002653
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hepatic control elements promote long-term expression of human coagulation factor IX gene in hydrodynamically transfected mice.
    Kim HS; Kim JC; Lee YK; Kim JS; Park YS
    J Gene Med; 2011 Jul; 13(7-8):365-72. PubMed ID: 21710610
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver.
    Nathwani AC; Gray JT; Ng CY; Zhou J; Spence Y; Waddington SN; Tuddenham EG; Kemball-Cook G; McIntosh J; Boon-Spijker M; Mertens K; Davidoff AM
    Blood; 2006 Apr; 107(7):2653-61. PubMed ID: 16322469
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dexamethasone Transiently Enhances Transgene Expression in the Liver When Administered at Late-Phase Post Long-Term Adeno-Associated Virus Transduction.
    Chai Z; Zhang X; Dobbins AL; Samulski RJ; Merricks EP; Nichols TC; Li C
    Hum Gene Ther; 2022 Feb; 33(3-4):119-130. PubMed ID: 34617445
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effective gene therapy for haemophilic mice with pathogenic factor IX antibodies.
    Markusic DM; Hoffman BE; Perrin GQ; Nayak S; Wang X; LoDuca PA; High KA; Herzog RW
    EMBO Mol Med; 2013 Nov; 5(11):1698-709. PubMed ID: 24106230
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Stable human FIX expression after 0.9G intrauterine gene transfer of self-complementary adeno-associated viral vector 5 and 8 in macaques.
    Mattar CN; Nathwani AC; Waddington SN; Dighe N; Kaeppel C; Nowrouzi A; Mcintosh J; Johana NB; Ogden B; Fisk NM; Davidoff AM; David A; Peebles D; Valentine MB; Appelt JU; von Kalle C; Schmidt M; Biswas A; Choolani M; Chan JK
    Mol Ther; 2011 Nov; 19(11):1950-60. PubMed ID: 21629224
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.